Prakash C. Deedwania

Q: What Schools Are Affiliated With Prakash C. Deedwania

Prakash C. Deedwania is affiliated with the following schools: University of Amsterdam, University of Florida, Stanford University, Case Western Reserve University, University of California, San Francisco, Columbia University

Prakash C. Deedwania's AcademicInfluence.com Rankings

Medical

#1748

World Rank

#2120

Historical Rank

Cardiology

#138

World Rank

#141

Historical Rank

medical Degrees

Prakash C. Deedwania

Philosophy

#5279

World Rank

#8037

Historical Rank

Logic

#2585

World Rank

#3597

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Prakash C. Deedwania's Degrees

Masters Medicine Delhi University
Doctorate Medicine Delhi University

Why Is Prakash C. Deedwania Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Prakash C. Deedwania's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) (1999) (4830)
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) (1997) (1718)
ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). (2003) (1549)
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. (2000) (1183)
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials (2009) (1158)
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. (1995) (1073)
Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. (2001) (952)
Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. (2006) (723)
Correction: Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy. (1998) (716)
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015) (626)
Effect of valsartan on the incidence of diabetes and cardiovascular events. (2010) (626)
Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. (1988) (567)
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. (2015) (497)
Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. (1998) (474)
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment (2008) (459)
Effect of nateglinide on the incidence of diabetes and cardiovascular events. (2010) (440)
Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. (2008) (417)
Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. (1989) (416)
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes (2006) (409)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. (2017) (403)
Consensus recommendations for the management of chronic heart failure: Introduction (1999) (391)
ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). (2003) (387)
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study (2006) (383)
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. (2012) (376)
Effects of Treatment on Outcome in Mildly Symptomatic Patients With Ischemia During Daily Life: The Atenolol Silent Ischemia Study (ASIST) (1994) (343)
Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. (1999) (332)
Silent ischemia during daily life is an independent predictor of mortality in stable angina. (1990) (331)
HFSA 2006 comprehensive heart failure practice guideline (2006) (329)
Prevalence of metabolic syndrome in an Indian urban population. (2004) (317)
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. (2008) (295)
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. (2005) (288)
Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. (2009) (279)
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. (2007) (266)
ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for P (1999) (247)
Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE) (2007) (225)
ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the guidelines for ambulatory electrocardiography). (1999) (224)
Regional variations in cardiovascular risk factors in India: India heart watch. (2012) (221)
Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. (1990) (219)
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association (2015) (217)
Metoprolol CR/XL in Female Patients With Heart Failure: Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) (2002) (216)
Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. (1996) (214)
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. (2003) (212)
Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism (2008) (208)
Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. (2004) (203)
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. (2003) (184)
Applying continuous chaotic modeling to cardiac signal analysis (1996) (181)
Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study (2007) (177)
Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes: Clinical Perspectives From the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. (2015) (170)
Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? (2003) (165)
Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study (2012) (157)
Identifying Heart Failure Patients at High Risk for Near-Term Cardiovascular Events With Serial Health Status Assessments (2007) (156)
Significance of Block Distal to the His Bundle Induced by Atrial Pacing in Patients with Chronic Bifascicular Block (1979) (152)
Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. (2015) (145)
The cardiovascular dysmetabolic syndrome. (1998) (142)
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial (2015) (137)
Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. (2002) (133)
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. (2005) (133)
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). (2005) (119)
Association of Educational, Occupational and Socioeconomic Status with Cardiovascular Risk Factors in Asian Indians: A Cross-Sectional Study (2012) (117)
Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. (2001) (114)
Silent myocardial ischemia. A clinical perspective. (1991) (114)
Mechanisms precipitating acute cardiac events: review and recommendations of an NHLBI workshop. National Heart, Lung, and Blood Institute. Mechanisms Precipitating Acute Cardiac Events Participants. (1997) (111)
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. (2005) (109)
Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. (2005) (108)
Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey (2019) (101)
Atrial fibrillation in heart failure: a comprehensive review. (2010) (99)
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. (2020) (98)
Tolerability of &bgr;-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) (2002) (97)
Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta. (1997) (96)
Ambulatory ECG‐Based T‐Wave Alternans Predicts Sudden Cardiac Death in High‐Risk Post‐MI Patients with Left Ventricular Dysfunction in the EPHESUS Study (2008) (95)
Efficacy, safety and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure (2004) (90)
Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. (2011) (88)
Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. (1991) (86)
Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. (1999) (85)
Normotension, prehypertension, and hypertension in urban middle-class subjects in India: prevalence, awareness, treatment, and control. (2013) (85)
Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity‐matched study (2011) (85)
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. (2019) (84)
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. (2014) (81)
Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial). (2010) (81)
Management issues in the metabolic syndrome. (2006) (79)
Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. (1987) (78)
Benefits of statin therapy and compliance in high risk cardiovascular patients (2010) (78)
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). (2002) (75)
Mechanisms of endothelial dysfunction in the metabolic syndrome (2003) (74)
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. (2008) (72)
Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). (2002) (69)
Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating β‐Blockers (2011) (68)
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). (2007) (67)
Prevalence of diabetes and cardiovascular risk factors in middle-class urban participants in India (2014) (65)
Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. (2011) (65)
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). (2010) (65)
Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction (2018) (65)
Twenty-year trends in cardiovascular risk factors in India and influence of educational status (2012) (61)
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). (2010) (60)
Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. (2014) (60)
Hypertension and diabetes: new therapeutic options. (2000) (60)
Prevalence and patterns of silent myocardial ischemia during daily life in stable angina patients receiving conventional antianginal drug therapy. (1990) (60)
In-utero and neonatal exposure to secondhand smoke causes vascular dysfunction in newborn rats. (1998) (60)
Clinical Significance of Prolonged Sinoatrial Conduction Time (1977) (58)
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association (2022) (58)
Frequent Atrial Premature Complexes and Their Association With Risk of Atrial Fibrillation. (2015) (55)
Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India (2009) (55)
Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF) (1997) (54)
High prevalence of metabolic syndrome among urban subjects in India: a multisite study. (2014) (54)
Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). (1997) (52)
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome (2016) (52)
Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: a cross sectional study. (2014) (51)
The progression from hypertension to heart failure. (1997) (51)
Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. (2011) (49)
Risk of Heart Failure and Death After Prolonged Smoking Cessation: Role of Amount and Duration of Prior Smoking. (2015) (48)
The deadly quartet revisited. (1998) (46)
Sites of conduction disease in aortic stenosis: significance of valve gradient and calcification. (1977) (46)
Comparative Effects of ACE Inhibitors and an Angiotensin Receptor Blocker on Atherosclerosis and Vascular Function (2001) (45)
Predictors of mortality in patients with heart failure. (1994) (45)
The key to unraveling the mystery of mortality in heart failure: an integrated approach. (2003) (45)
Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure. (2016) (45)
Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. (1999) (44)
Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: findings from a population-based cohort study. (2013) (44)
Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. (2005) (44)
Current treatment options for the metabolic syndrome (2005) (44)
Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. (2011) (43)
Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke. (1999) (42)
New oral anticoagulants in elderly patients with atrial fibrillation. (2013) (42)
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure (2011) (42)
Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. (2002) (42)
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives (2010) (41)
Evidence-Based, Cost-effective Risk Stratification and Management After Myocardial Infarction (1997) (41)
Metabolic and Antihypertensive Effects of Combined Angiotensin Receptor Blocker and Diuretic Therapy in Prediabetic Hypertensive Patients With the Cardiometabolic Syndrome (2008) (40)
Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. (2019) (40)
Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers (2014) (40)
Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. (2004) (40)
Increased variance in blood pressure distribution and changing hypertension prevalence in an urban Indian population (2003) (40)
Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). (2010) (39)
Selective and Specific Inhibition of If with Ivabradine for the Treatment of Coronary Artery Disease or Heart Failure (2013) (39)
25-Year trends in hypertension prevalence, awareness, treatment, and control in an Indian urban population: Jaipur Heart Watch (2017) (38)
Congestive heart failure: Survival trial of antiarrhythmic therapy (CHF STAT) (1992) (38)
A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina) (2002) (38)
Chronic dietary L-arginine prevents endothelial dysfunction secondary to environmental tobacco smoke in normocholesterolemic rabbits. (1997) (37)
Low high-density lipoprotein cholesterol: current status and future strategies for management (2010) (36)
Underutilization of evidence-based therapy in heart failure. An opportunity to deal a winning hand with ace up your sleeve. (1997) (36)
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. (2011) (36)
Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure. (2016) (36)
Electrophysiologic Effects of Lidocaine on Sinus Node and Atrium in Patients with and without Sinoatrial Dysfunction (1978) (35)
Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. (2015) (35)
Angiotensin-converting enzyme inhibitors in congestive heart failure. (1990) (34)
Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves. (2011) (34)
Coronary artery disease in South Asians: evolving strategies for treatment and prevention. (2005) (34)
Obesity is major determinant of coronary risk factors in India: Jaipur Heart Watch studies. (2008) (34)
Usefulness of ambulatory silent myocardial ischemia added to the prognostic value of exercise test parameters in predicting risk of cardiac death in patients with stable angina pectoris and exercise-induced myocardial ischemia. (1991) (33)
Blood pressure control in diabetes mellitus: is lower always better, and how low should it go? (2011) (33)
Veterans Affairs congestive heart failure antiarrhythmic trial. CHF STAT Investigators. (1993) (32)
Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research Investigators. (1998) (31)
Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. (2017) (30)
Effects of second-hand smoke and gender on infarct size of young rats exposed in utero and in the neonatal to adolescent period. (1997) (30)
Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes. (2004) (30)
Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure. (2019) (30)
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. (2015) (30)
Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. (2020) (29)
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). (2009) (29)
Fractal and complexity measures of heart rate dynamics after acute myocardial infarction. (2001) (29)
Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. (2004) (29)
Calcium Channel Blockers and Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction (2014) (28)
Care and Outcomes of Asian-American Acute Myocardial Infarction Patients: Findings From the American Heart Association Get With The Guidelines-Coronary Artery Disease Program (2012) (28)
Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexes. (1990) (28)
Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). (2003) (28)
The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. (2005) (28)
The epidemiology and pathophysiology of heart failure. (2012) (28)
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. (2020) (27)
The Anti-Ischemic and Anti-Anginal Properties of Statins (2010) (27)
Exercise test predictors of ambulatory silent ischemia during daily life in stable angina pectoris. (1990) (27)
A conjecture to the solution of the continuous Logistic equation (1994) (27)
Obesity is rarely healthy. (2018) (26)
Dyslipidemia in special populations: Asian Indians, African Americans, and Hispanics (2006) (26)
The changing face of hypertension: is systolic blood pressure the final answer? (2002) (26)
Coronary heart disease and risk factors in Asian Indians. (2001) (25)
Dangers and Long-Term Outcomes in Metabolically Healthy Obesity: The Impact of the Missing Fitness Component. (2018) (25)
Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. (2011) (24)
Evidence-based therapy for heart failure. (2012) (24)
Cardiovascular outcome trials of the newer anti-diabetic medications. (2019) (23)
Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. (2003) (23)
Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. (2005) (23)
Asymptomatic ischemia during predischarge Holter monitoring predicts poor prognosis in the postinfarction period. (1993) (23)
A new approach for indirect recording of anterior left atrial activation in man. (1977) (23)
The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies (2012) (23)
Beta-Adrenergic Blockers for Chronic Heart Failure (2009) (22)
An update on pharmacotherapies in diabetic dyslipidemia. (2019) (22)
Low Prevalence of AHA-Defined Ideal Cardiovascular Health Factors: A Study of Urban Indian Men and Women. (2017) (22)
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. (2009) (22)
The Role of Renin-Angiotensin Agents in Altering the Natural History of Type 2 Diabetes Mellitus (2010) (21)
Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trials (2007) (21)
Impact of atrial fibrillation and heart failure, independent of each other and in combination, on mortality in community-dwelling older adults. (2014) (21)
Increased Demand Versus Reduced Supply and the Circadian Variations in Ambulatory Myocardial Ischemia Therapeutic Implications (1993) (21)
Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.). (2014) (21)
Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. (2017) (21)
Isolated diastolic hypertension and incident heart failure in community-dwelling older adults: Insights from the Cardiovascular Health Study. (2017) (21)
Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. (2018) (21)
The Benefits of Intensive Lipid Lowering in Patients With Stable Coronary Heart Disease With Normal or High Systolic Blood Pressure: An Analysis of the Treating to New Targets (TNT) Study (2008) (21)
Hemodynamic changes as triggers of cardiovascular events. (1996) (21)
Endothelium: a new target for cardiovascular therapeutics. (2000) (21)
Cardiovascular Protection with Anti-hyperglycemic Agents (2019) (21)
Effects of Add‐On Nebivolol on Blood Pressure and Glucose Parameters in Hypertensive Patients With Prediabetes (2013) (20)
Diastolic dysfunction and autonomic abnormalities in patients with systolic heart failure (2007) (20)
Role of beta blockade in the treatment of myocardial ischemia. (1997) (20)
An Overview of Glycemic Control in the Coronary Care Unit with Recommendations for Clinical Management (2009) (20)
Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. (2016) (19)
Role of myocardial oxygen demand in the pathogenesis of silent ischemia during daily life. (1992) (19)
Beta blockers in combination with class I antiarrhythmic agents. (1987) (19)
Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. (1995) (19)
Mental stress, pain perception and risk of silent ischemia. (1995) (19)
Statins in Chronic Kidney Disease: Cardiovascular Risk and Kidney Function (2014) (18)
Association between depression and readmission of heart failure: A national representative database study. (2020) (18)
Silent Myocardial Ischaemia in the Elderly (2000) (18)
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial (2015) (18)
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). (2012) (17)
Geographic epidemiology of cardiometabolic risk factors in middle class urban residents in India: cross–sectional study (2015) (17)
The Prognostic and Economic Implications of a Strategy to Detect and Treat Asymptomatic Ischemia: The Atenolol Silent Ischemia Trial (ASIST) Protocol (1991) (17)
Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. (2005) (17)
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes (2020) (17)
Silent ischemia predicts poor outcome in high-risk healthy men. (2001) (17)
Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. (2006) (17)
Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial (2018) (17)
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). (2011) (17)
Role of Emerging Antithrombotic Therapy in the Prevention of Cardioembolic Complications in Patients with Atrial Fibrillation (2011) (16)
Efficacy and Safety Comparison of Nitrendipine and Hydralazine as Antihypertensive Monotherapy (1984) (16)
Educational status-related disparities in awareness, treatment and control of cardiovascular risk factors in India (2015) (16)
Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease. (2016) (16)
Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. (2017) (16)
Antioxidant diet preserves endothelium-dependent vasodilatation in resistance arteries of hypercholesterolemic rabbits exposed to environmental tobacco smoke. (1998) (16)
Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina. (2011) (16)
Interventions for cardiovascular disease prevention. (2011) (15)
Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients. (2012) (15)
A hybrid system for diagnosis and treatment of heart disease (1994) (15)
Trends of Cardiac Complications in Patients With Rheumatoid Arthritis: Analysis of the United States National Inpatient Sample; 2005-2014. (2019) (15)
American Heart Association Diabetes and Cardiometabolic Health Summit: Summary and Recommendations (2018) (14)
Prevention of and Medical Therapy for Atrial Arrhythmias in Heart Failure (2002) (14)
Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension (2011) (14)
Risk of Heart Failure and Death After Prolonged Smoking CessationCLINICAL PERSPECTIVE (2015) (14)
Amlodipine once a day in stable angina: Double‐blind crossover comparison with placebo (1993) (14)
Endothelin, the bad actor in the play: a marker or mediator of cardiovascular disease. (1999) (14)
How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). (2003) (14)
Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change. (2000) (14)
Global risk assessment in the presymptomatic patient. (2001) (14)
Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. (2009) (14)
Prevalence and prognosis of heart failure. (1994) (13)
Is there evidence in support of the ischemia suppression hypothesis? (1994) (13)
Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving β-blockers: insights from the BEST trial. (2013) (13)
Mechanism of the deadly quartet. (2000) (13)
Diabetes, cardiovascular disease, and ethnicity. (2013) (13)
Effects of beta-adrenergic stimulation on atrial latency and atrial vulnerability in patients with paroxysmal supraventricular tachycardia. (1988) (13)
Clinical significance of cardiovascular dysmetabolic syndrome (2002) (13)
Atrial fibrillation in heart failure. (2012) (13)
SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality? (2019) (13)
Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population (2009) (13)
Diabetes and vascular disease (2008) (12)
Gaps in guideline implementation: a cause for concern, time for action. (2015) (12)
Secondary prevention after myocardial infarction. Too many choices, which ones work? (1993) (12)
Compliance with guideline‐directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines–Coronary Artery Disease (GWTG‐CAD) program (2017) (12)
Strategies for Promotion of a Healthy Lifestyle in Clinical Settings: Pillars of Ideal Cardiovascular Health: A Science Advisory From the American Heart Association. (2021) (12)
A propensity-matched study of the association of diabetes mellitus with incident heart failure and mortality among community-dwelling older adults. (2011) (12)
Effects of Antioxidant Vitamins C and E on Atherosclerosis in Lipid-Fed Rabbits (1998) (12)
Nocturnal atrioventricular block as a manifestation of sleep apnea syndrome. (1979) (12)
Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim phamacodynamic results of the SOAR study (1998) (12)
Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study). (2016) (12)
Digoxin Initiation and Outcomes in Patients with Heart Failure (HFrEF and HFpEF) and Atrial Fibrillation. (2020) (12)
Measurement of variability in Holter tape R-R intervals for patients with congestive heart failure (1994) (12)
Management of coronary artery disease in patients with type 2 diabetes mellitus (2007) (11)
Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals: Insights From the Beta-blocker Evaluation of Survival Trial (BEST) (2014) (11)
Tophaceous pseudogout of the mitral valve. (1998) (11)
Ventricular arrhythmias in heart failure: to treat or not to treat? (1994) (11)
Early invasive versus ischaemia-guided strategies in the management of non-Q wave myocardial infarction patients with and without prior myocardial infarction; results of Veterans Affairs Non-Q Wave Infarction Strategies in Hospital (VANQWISH) trial. (2000) (11)
Effect of morning versus evening dosing of diltiazem on myocardial ischemia detected by ambulatory electrocardiographic monitoring in chronic stable angina pectoris. Dilacor XR Ambulatory Ischemia Study Group. (1997) (11)
Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis. (2004) (11)
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). (2004) (11)
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial. (2014) (11)
Effect of age on atrioventricular conduction in patients with chronic bifascicular block. (1980) (11)
The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. (2009) (11)
Similar efficacy of nitrendipine in young and elderly hypertensive patients. (1987) (10)
Current Controlled Trials in Cardiovascular Medicine (2002) (10)
The need for a cost-effective strategy to detect ambulatory silent ischemia. (1994) (10)
Chaotic ECG analysis using combined models (1998) (10)
The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified? (2015) (10)
A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease. (1998) (10)
Trials and tribulations associated with angina and traditional therapeutic approaches (2007) (10)
Does myocardial ischemia portend poor prognosis? (1994) (10)
Reducing morbidity and mortality in high risk patients with statins (2009) (10)
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation (2012) (9)
The pharmacologic management of heart disease (1997) (9)
Increased myocardial oxygen demand and ischemia during daily life: resurrection of an age-old concept. (1992) (9)
Silent myocardial ischemia and its relationship to acute myocardial infarction. (1986) (9)
Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. (2020) (9)
Coronary angiographic findings after non-Q-wave myocardial infarction: An analysis from the VANQWISH trial (1996) (9)
Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. (2019) (9)
Rheumatic heart disease and risk of incident heart failure among community-dwelling older adults: A prospective cohort study (2012) (8)
Impact of the 2017 ACC/AHA guidelines on the prevalence of hypertension among Indian adults: Results from a cross-sectional survey☆ (2020) (8)
Angiotensin receptor blockers: novel role in high-risk patients. (2008) (8)
Contemporary approaches in medical management of patients with stable coronary artery disease. (1995) (8)
Treating female heart failure patients with metoprolol CR/XL (2002) (8)
Double-blind comparison of doxazosin, nadolol, and placebo in patients with mild-to-moderate hypertension (1988) (8)
Ivabradine in Heart Failure (2012) (8)
Evidence-based, cost-effective risk stratification and management after myocardial infarction. California Cardiology Working Group on Post-MI Management. (1997) (7)
Anti-ischemic effects of amlodipine in patients with stable angina pectoris and myocardial ischemia during daily life. Amlodipine Study Group. (1999) (7)
ESSENTIAL – The Studies of Oral Enoximone Therapy in Advanced Heart Failure (2005) (7)
A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. (2013) (7)
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. (2021) (7)
Getting with the ACC/AHA guidelines for the treatment of chronic angina as a disease state. (2009) (7)
Combining ECG analysis with clinical parameters for diagnosis of heart failure (1997) (7)
Systemic and coronary hemodynamic effects of bepridil in patients with depressed left ventricular function. (1992) (7)
Should asymptomatic subjects with silent ischemia undergo further evaluation and follow-up? (1994) (6)
Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure. (2017) (6)
Electrophysiologic observations in a patient with bradycardia-dependent atrioventricular block. (1978) (6)
Ambulatory electrocardiographic monitoring for myocardial ischemia. (2001) (6)
Updated risk factors should be used to predict development of diabetes. (2017) (6)
Atrial fibrillation in patients with heart failure: pharmacologic options. (2001) (6)
Hypercholesterolemia. Is lipid-lowering worthwhile for older patients? (2000) (6)
Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. (2020) (6)
Effects of antioxidant vitamins C and E on atherosclerosis in lipid-fed rabbits. (1994) (6)
Aspirin for Primary Prevention of Coronary Artery Disease. (2020) (6)
Angiotensin Receptor Blockers: Cardiovascular Protection in the Metabolic Syndrome (2006) (6)
Ambulatory electrocardiography evaluation of asymptomatic, unstable, and stable coronary artery disease patients for myocardial ischemia. (1992) (6)
Anticoagulation in Atrial Fibrillation: Is the Paradigm Really Shifting? (2017) (6)
The rational use of diuretics in heart failure (2003) (5)
Expanding roles for atorvastatin. (2008) (5)
The Ongoing Saga of Optimal Blood Pressure Level in Patients With Diabetes Mellitus and Coronary Artery Disease (2018) (5)
Outcomes in younger and older adults with chronic advanced systolic heart failure: a propensity-matched study. (2012) (5)
Congestive heart failure: survival trial of antiarrhythmic therapy (CHF STAT). The CHF STAT Investigators. (1992) (5)
Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). (2006) (5)
New York Heart Association functional class influences the impact of diabetes on cardiac autonomic function. (2010) (5)
Sunday, 26 August 2012 (2012) (5)
L-Arginine restores normal endothelium-mediated relaxation in hypercholesterolemic rabbits exposed to tobacco smoke (1996) (5)
Cardiovascular Impact of Race and Ethnicity in Patients With Diabetes and Obesity: JACC Focus Seminar 2/9. (2021) (5)
Randomized Placebo-Controlled Withdrawal Study of Amlodipine in Agina Pectoris. (1995) (5)
Management of Patients With Stable Angina and Type 2 Diabetes. (2015) (4)
Emerging strategies for diabetes and cardiovascular disorders: Introduction and foreword. (2019) (4)
Transient myocardial ischemia and its relation to determinants of myocardial oxygen demand. (1990) (4)
Prevention of heart failure and postinfarction remodeling. (1994) (4)
Polymorphisms and Noncardioembolic Stroke in Three Case-Control Studies (2011) (4)
Bedside evaluation of cardiac markers (2005) (4)
Secondary Prevention With Calcium Antagonists After a Myocardial Infarction-Reply (1993) (4)
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation (2015) (4)
Pharmacotherapy of hypertension in patients with diabetes mellitus (2001) (4)
Triggers and timing of coronary events and sudden cardiac death. (1994) (4)
Dangers of Hypoglycemia in Cardiac Patients With Diabetes: Time to Switch to Safer, Newer Drugs. (2018) (4)
Computer Applications in Medical Care. Computer Systems in Hospitals. Hospital-Based Specialty Care Systems: Evaluation of EMERGE, a Medical Decision Making Aid for Analysis of Chest Pain (1983) (4)
DISCHARGE INITIATION OF ACE INHIBITORS OR ARBS IS ASSOCIATED WITH SIGNIFICANTLY LOWER 30-DAY ALL-CAUSE READMISSION IN HOSPITALIZED OLDER PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION (2014) (4)
Evolving Treatment Options for Prevention of Cardiovascular Events in High‐Risk Hypertensive Patients (2007) (4)
Hypertension as a cardiometabolic risk. (2010) (4)
Analysis of Holter data for indications of congestive heart failure using continuous chaotic modeling (1996) (4)
Prediabetes and the risk of diabetes (2012) (4)
Risk of diabetes and cardiovascular disease: best to return back to the basics: comment on "Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus". (2010) (4)
Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim safety and tolerability results of the SOAR study (1998) (4)
Monday, 27 August 2012 (2012) (3)
Early intervention in patients with heart failure and left ventricular dysfunction. (1995) (3)
Role of medical versus interventional strategies to prevent coronary events in patients with stable coronary artery disease. (2011) (3)
The current state of beta blockers in hypertension therapy. (2010) (3)
DIABETES IS AN INDEPENDENT RISK FACTOR FOR HEART FAILURE AMONG COMMUNITY DWELLING OLDER ADULTS (2010) (3)
How do we best treat patients with ischemic heart disease? (1998) (3)
Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation (2015) (3)
Amiodarone is more effective than placebo for spontaneous restoration and maintenance of sinus rhythm in patients with chronic artial fibrillation and congestive heart failure (1996) (3)
2P-0586 Rosuvastatin compared with atorvastatin, simvastatin, and pravastatin for lipid ratios (STELLAR trial results) (2003) (3)
Cardiometabolic-Renal Disease in South Asians: Consensus Recommendations from the Cardio Renal Society of America (2019) (3)
Double-blind crossover comparison of amlodipine at three dose levels and placebo in chronic stable angina. (1989) (3)
820-1 Comparative effects of statins on atherogenic dyslipidemia in patients with the metabolic syndrome (2004) (3)
Income disparity and incident cardiovascular disease in older Americans. (2021) (3)
Evidence-Based Policy Making for Public Health Interventions in Cardiovascular Diseases: Formally Assessing the Feasibility of Clinical Trials. (2020) (3)
SHOULD WE ANTICOAGULATE PATIENTS WITH ADVANCED SYSTOLIC HEART FAILURE WITHOUT ATRIAL FIBRILLATION? INSIGHTS FROM THE BETA-BLOCKER EVALUATION OF SURVIVAL TRIAL (BEST) (2010) (3)
Endothelium-dependent vasodilation is impaired in healthy offspring of hypertensive parents. (2011) (3)
Pharmacotherapy in congestive heart failure: Do NSAIDs attenuate the therapeutic effect of ACE inhibitors in heart failure patients? (1999) (3)
Modern Pharmacologic Strategies in the Management of Atrial Fibrillation (2011) (3)
1P-0290 Designs of 3 trials comparing rosuvastatin and atorvastatin in African American, South Asian, and Hispanic patients: ARIES, IRIS and STARSHIP trials (2003) (3)
HYPERCHOLESTEROLEMIA AWARENESS, TREATMENT AND CONTROL IN HIGH CARDIOVASCULAR RISK SUBJECTS IN INDIA: A POPULATION-BASED STUDY (2013) (3)
Assessment of Lung Cancer Risk Among Smokers for Whom Annual Screening Is Not Recommended. (2022) (3)
Is silent myocardial ischemia clinically important? Does it have prognostic significance? (1989) (2)
Significance of arrhythmias in congestive heart failure. (1988) (2)
Treating non-ST-segment elevation ACS (2005) (2)
Abstract 13555: Acute Efficacy of Sodium Zirconium Cyclosilicate (ZS-9) in Patients on Mineralocorticoid-Receptor Antagonists: Analysis From Two Phase 3 Studies (2015) (2)
Testosterone, but not estradiol, attenuates acetyicholine-induced relaxation of tobacco smoke-exposed hypercholesterolemic rabbit aorta (1996) (2)
Statins in heart failure. (2008) (2)
GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice. (2022) (2)
An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs. (2012) (2)
CURRENT THERAPEUTIC OPTIONS AND EVOLVING THERAPIES FOR CHRONIC STABLE ANGINA / CHRONIC CORONARY SYNDROME * — (2006) (2)
759–4 Information Integration for Cardiology Decision Support (1995) (2)
Tu-W20:6 First large randomized trial of statin therapy in South Asian patients at risk for coronary heart disease: The iris trial (2006) (2)
PM316 Depression, Chronic Stress, Or Both, And Cardiovascular Risk Factors: A Cross Sectional Study Among Urban Subjects In India (2014) (2)
O170 Educational-status related inequities in awareness, treatment and control of cardiovascular risk factors in India: Cross-sectional study (2014) (2)
Calcium channel blockers. (1982) (2)
Treatment of systolic hypertension and low diastolic blood pressure in older adults: How low is too low?! (2017) (2)
IS PRE-DIABETES ASSOCIATED WITH INCREASED MORTALITY AND CARDIOVASCULAR MORBIDITY IN COMMUNITY-DWELLING OLDER ADULTS? (2010) (2)
Lack of effect of two calcium-entry blockers (diltiazem and nifedipine) on serum parathyroid hormone and calcium (1982) (2)
A neural network model for analysis of prognostic factors in congestive heart failure (1996) (2)
Comparison of the prognostic values of ischemia during daily life and ischemia induced by treadmill exercise testing. (1994) (2)
Abstract 3731: Intensive Lipid Lowering with Atorvastatin is Associated with Significant Cardiovascular Benefits in Patients with and without Chronic Kidney Disease: The Treating to New Targets (TNT) Study (2006) (2)
Dyslipidemia and lipid-lowering therapy in the elderly (2005) (2)
RANDOMIZED PLACEBO‐CONTROLLED WITHDRAWAL STUDY OF AMLODIPINE IN ANGINA PECTORIS (1995) (2)
Initiation of Anti-Hypertensive Drugs and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. (2021) (2)
Treating hypertension in patients with diabetes. (2002) (2)
Primary Prevention of Atrial Fibrillation - The Path Untread. (2013) (2)
CHRONIC OPIOID USE IS ASSOCIATED WITH SIGNIFICANT HIGHER 12-MONTH ALL-CAUSE READMISSION AND ALL-CAUSE MORTALITY BUT NOT ASSOCIATED WITH 30-DAY ALL-CAUSE READMISSION OR ALL-CAUSE MORTALITY IN OLDER MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE (2016) (2)
Is Increased Use of Mechanical Circulatory Support Devices Justified? A Cause for Concern. (2015) (2)
Does the metabolic syndrome help to select patients requiring high statin dose (2006) (2)
Corrigendum to "Systolic-diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the cardiovascular health study" [Int. J. Cardiol. 235 (2017) 11-16]. (2017) (2)
Non-antiarrhythmic Therapies for Cardiac Arrhythmias (2012) (2)
EFFICACY AND SAFETY OF LONG-TERM EVOLOCUMAB USE IN ASIAN VERSUS OTHER SUBJECTS: THE FOURIER TRIAL (2019) (2)
Hearty Breakfast for Healthier Arteries. (2017) (2)
The Council for Myocardial Ischemia and Infarction: advisory group reports on silent myocardial ischemia, heart rate control, and post-myocardial infarction management. (1992) (2)
Using chaotic measures to summarize medical signal analysis (1999) (2)
Contemporary approaches for cardiovascular risk reduction in diabetes. (2009) (2)
Prevention of Cardiovascular Disease: A Continuum, an Issue of Cardiology Clinics (2011) (2)
Sotalol Is More Powerful Than Propranolol in Suppressing Complex Ventricular Arrhythmias (1997) (2)
Baseline Hypokalemia and Long-Term Outcomes in Ambulatory Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and New York Heart Association Class III-IV: A Propensity-Matched Study of Beta-Blocker Evaluation of Survival Trial (BEST) (2016) (1)
The Role of Angiotensin Receptor Blockers in Cardiovascular Protection Beyond Blood Pressure Control (2006) (1)
Residual risk in TNT (2012) (1)
Chapter 6 – The Metabolic Syndrome and Its Effects on Cardiovascular Risks (2006) (1)
ISOLATED SYSTOLIC HYPERTENSION (ISH) BY NEW ACC/AHA HYPERTENSION (HTN) GUIDELINES AND OUTCOMES IN OLDER ADULTS OVER 23 YEARS IN THE CARDIOVASCULAR HEALTH STUDY (CHS) (2019) (1)
Anti-ischemic properties of ACE-inhibitors. (1996) (1)
Olmesartan‐based monotherapy vs combination therapy in hypertension: A meta‐analysis based on age and chronic kidney disease status (2017) (1)
Risk of Stroke in Older Adults With Heart Failure. (2022) (1)
Metabolic syndrome is highly prevalent in patients with coronary artery disease (2003) (1)
Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes (2011) (1)
Information integration in a decision support system. (1994) (1)
Circadian pattern of non-Q-wave myocardial infarction: Effects of beta blockers, calcium blockers and aspirin (1996) (1)
1. Renewed Understanding of the Pathophysiology of Heart Failure 1 (2013) (1)
ORTHOSTATIC HYPOTENSION: A NEW RISK FACTOR FOR INCIDENT HEART FAILURE IN COMMUNITY-DWELLING OLDER ADULTS (2011) (1)
Ivabradine in heart failure: hope or hype? (2012) (1)
Abstract 18649: Comparative Impact of Isolated Systolic Hypertension vs Systolic-Diastolic Hypertension on Incident Heart Failure and All-Cause Mortality in Community-Dwelling Older Adults (2014) (1)
Lipid-lowering therapy (2012) (1)
Current perspectives in treatment of angina pectoris. (1986) (1)
Heart failure: a common and complex clinical syndrome. (2012) (1)
Diabetes is the most prevalent risk factor for premature vascular disease in migrant Asian Indians (2002) (1)
Defining the Role of Icosapent Ethyl in Clinical Practice (2020) (1)
Implications of a Continuous Approach to Chaotic Modeling (1994) (1)
Differential diagnosis using signal analysis data (1999) (1)
Abstract 085: Discordance in Patient-Physician Perceptions of Angina Experiences and Delivery of Care (2017) (1)
Poster Discussion Sessions (2009) (1)
The Cardiovascular Dysmetabolic Syndrome : proceedings of a symposium (1998) (1)
In-Hospital Weight Loss and Outcomes in Patients with Heart Failure (2021) (1)
Hemodynamic variability and myocardial ischemia. (1995) (1)
Significance of fascicular block complicating acute myocardial infarction. (1980) (1)
Right Ventricular Ejection Fraction and Beta-Blocker Effect in Heart Failure with Reduced Ejection Fraction: Beta-Blocker and outcomes in HFrEF by RVEF. (2021) (1)
Dyslipidemia in the Metabolic Syndrome (2006) (1)
Diabetes and Cardiovascular Disease (2004) (1)
Therapeutic strategies in diabetes and cardiovascular disease (2005) (1)
Erratum: Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers (Journal of the American College of Cardiology (2011) 57 (63-69)) (2013) (1)
CARE AND OUTCOMES OF ASIAN ACUTE MYOCARDIAL INFARCTION PATIENTS: RESULTS FROM THE AMERICAN HEART ASSOCIATION GET WITH THE GUIDELINES-CORONARY ARTERY DISEASE PROGRAM (2011) (1)
LOW RIGHT VENTRICULAR EJECTION FRACTION: A POTENTIAL EXPLANATION FOR RACIAL DIFFERENCES IN MORTALITY IN ADVANCED SYSTOLIC HEART FAILURE IN THE BETA-BLOCKER EVALUATION OF SURVIVAL TRIAL (2013) (1)
Treating dyslipidemia in high-risk patients: case reviews and discussion. (2004) (1)
Metabolic Syndrome and Cardiovascular Disease: Epidemiology, Pathophysiology, and Therapeutic Considerations (2006) (1)
Outcome in Mildly Symptomatic Patients With Ischemia During Daily Life (2005) (1)
POOR OUTCOMES ASSOCIATED WITH DIGOXIN DISCONTINUATION IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) MAY DIFFER BY BETA-BLOCKER USE (2020) (1)
THE TRP719ARG VARIANT OF KIF6 AND CARDIOVASCULAR OUTCOMES IN STATIN-TREATED, CORONARY STABLE PATIENTS OF THE TNT AND IDEAL PROSPECTIVE STUDIES (2011) (1)
Clinical relevance of ischemia induced by mental stress (1997) (1)
Racial differences in mortality in patients with advanced systolic heart failure: potential role of right ventricular ejection fraction. (2014) (1)
Lack of Association Between Spironolactone Use and 30-Day All-Cause Readmission In Hospitalized Medicare Beneficiaries With Systolic Heart Failure Eligible for Spironolactone Therapy (2014) (1)
624 THE TRP719ARG VARIANT OF KIF6 AND CARDIOVASCULAR OUTCOMES IN STATIN-TREATED CORONARY STABLE PATIENTS OF THE TNT AND IDEAL PROSPECTIVE STUDIES (2011) (1)
Abstract 14207: C-Reactive Protein and Lipid Levels to Predict the Risk of Coronary Heart Disease in Statin-Treated Stable Coronary Patients: Prospective Results From the Treating to New Targets (TNT) Study (2010) (1)
Abstract 848: Improvement in Estimated Glomerular Filtration Rate With Atorvastatin in Patients With Metabolic Syndrome: The Treating to New Targets Study (2009) (1)
707-5 Functional Correlates and Prognostic Importance of Chronic Atrial Fibrillation in Patients with Dilated Cardiomyopathy and CHF (1995) (1)
3P-0915 Rationale and design of the Study Assessing Goals in the Elderly (SAGE): a comparison of aggressive versus moderate lipid-lowering therapy on myocardial ischemia in the elderly (2003) (1)
Is noninvasive testing necessary for all patients undergoing preoperative risk assessment: the predictive value of clinical variables in patients with peripheral vascular disease (1998) (1)
SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics (2021) (1)
Th-P16:267 Results of 3 North American trials (ARIES, IRIS, STARSHIP) comparing rosuvastatin and atorvastatin in African Americans, South Asians, and hispanics (2006) (1)
Chronic Kidney Disease and Higher Risk of 30-Day All-Cause Readmissions in Heart Failure: Findings from a Propensity-Matched Study (2014) (1)
The metabolic syndrome and obesity: management issues. (2007) (1)
Can ambulatory monitoring identify high-risk patients with stable coronary artery disease? (1997) (1)
PREDICTION OF CARDIOVASCULAR EVENTS IN STATIN-TREATED STABLE CORONARY PATIENTS WITH METABOLIC SYNDROME BY 18 NOVEL BIOMARKERS: THE TREATING TO NEW TARGETS (TNT) TRIAL (2010) (1)
COMMENTARY: Avoid the rush to judgment in acute coronary syndromes (2005) (1)
Tuesday, 28 August 2012 (2012) (1)
Lipoprotein(a) in patients who have non-insulin-dependent diabetes with and without coronary artery disease. (1997) (1)
ASSOCIATION OF ATRIAL FIBRILLATION AND OUTCOMES IN OLDER PATIENTS WITH HEART FAILURE WITH PRESERVED AND REDUCED EJECTION FRACTION (HFPEF AND HFREF) (2019) (1)
Preface cardiovascular disease prevention: the continuum of primary and secondary prevention. (2011) (1)
Aldosterone Antagonism With Eplerenone Does Not Adversely Affect Plasma Glucose Levels in Patients With Diabetes Mellitus: Findings From a Post Hoc Analysis of the EPHESUS Trial (2010) (1)
Differential diagnosis in cardiology: Combination of three approaches (1999) (1)
CHAPTER 42 – Special Patient Populations: Lipid Abnormalities in High-Risk Ethnic Groups (2009) (0)
Sites of Conduction Disease in Aortic Stenosis (2020) (0)
Chapter 42 – Hypertension in South Asians (2007) (0)
To the Editor, (2006) (0)
Abstract 19999: A Drop in Admission Serum Creatinine is Prognostically Similar to a Rise in Admission Serum Creatinine in Hospitalized Medicare Beneficiaries with Heart Failure: Impact on 30-Day All-Cause Readmission (2014) (0)
RELATIONSHIP BETWEEN BASELINE LIPOPROTEIN PARAMETERS AND CHRONIC KIDNEY DISEASE IN CORONARY PATIENTS (2013) (0)
Differential Association of Insulin Resistance and Metabolic Syndrome With Acute Myocardial Infarction and All-Cause Mortality in Older Adults (2010) (0)
Chapter-003 Cholesterol Management: Lessons Learned from the Recent Trials and Guidelines and their Relevance to Indian Scenario (2016) (0)
Correction: Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial (vol 73, pg 2961, 2019) (2019) (0)
Increased, tissue plasminogen activator antigen is predictive of cardiovascular events in the Veterans Affairs HDL Intervention Trial (VA-HIT) (2002) (0)
PLASMA NOR-EPINEPHRINE LEVELS AND MORTALITY IN PATIENTS WITH ADVANCED CHRONIC SYSTOLIC HEART FAILURE: INSIGHTS FROM THE BEST STUDY (2010) (0)
Differing Predictive Value of LDL Cholesterol and Systolic Blood Pressure on Components of CV Events in 21,727 High-Risk Patients With CHD and/or Diabetes: Pooled Analyses of TNT, IDEAL, and CARDS Trials (2011) (0)
Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers (Retraction of vol 57, pg 63, 2011) (2013) (0)
Drug And Device Selection In Heart Failure (2014) (0)
Abstract 15861: Natural History of Atrial Fibrillation, HF With Preserved and Reduced Ejection Fraction in Community Dwelling Older Adults (2014) (0)
Efficacy, Safety And Tolerability Of Metoprolol Cr/Xl InDiabetic Patients With Chronic Heart Failure (2005) (0)
Abstract 20774: Discharge Heart Rate and Outcomes in Hospitalized Patients With Heart Failure and Preserved Ejection Fraction (HFpEF) and Stable Admission-to-Discharge Heart Failure (2016) (0)
New exercise parameter for the identification of severe coronary artery disease. (1989) (0)
Beta-Blocker Use and Outcomes in Nursing Home Residents with Heart Failure with Reduced Ejection Fraction. (2021) (0)
Normalization of Serum Potassium With Sodium Zirconium Cyclosilicate (ZS-9) in Patients With Heart Failure (2015) (0)
INITIATION OF LOOP DIURETIC THERAPY IS ASSOCIATED WITH A LOWER RISK OF 30-DAY ALL-CAUSE READMISSION IN PATIENTS WITH HEART FAILURE NOT RECEIVING DIURETICS PRIOR TO HOSPITALIZATION (2018) (0)
Depression, Stress, and Cardiovascular Risk Factors in India Heart Watch: A Population-Based Cross Sectional Study (2021) (0)
Sleep Apnea Syndrome (2017) (0)
Abstract 17212: 30-day All-cause Readmission is Associated With a Significantly Higher Subsequent All-cause Mortality and Costly Readmissions Among Older Medicare Beneficiaries Hospitalized for Heart Failure (2015) (0)
Medical Treatment of Hypertension in Patients with Heart Failure with Preserved Ejection Fraction (2013) (0)
Abstract 15748: Alirocumab Efficacy and Safety by Race and Ethnicity: Analysis From Three ODYSSEY Phase 3 Trials (2017) (0)
Angiotensin-Converting Enzyme Inhibitors (ACE) in Congestive Heart Failure-Reply (1991) (0)
Lower Discharge Systolic Blood Pressure (SBP) and Poor Outcomes Among Hospitalized Patients With Heart Failure and Reduced Ejection Fraction (HFrEF) and Stable Admission-to Discharge SBP (2017) (0)
RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AND ADVANCED KIDNEY DISEASE (2022) (0)
Mechanical Circulatory Support and Rationale for Future Research-Reply. (2016) (0)
436 PARADOXICAL RESPONSE OF URINE ALBUMIN EXCRETION ASSOCIATED WITH ORAL GLUCOSE CHALLENGE IN TYPE 2 DIABETES. (2007) (0)
SMOKING AND OUTCOMES IN OLDER PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION (HFPEF) (2018) (0)
Meta-analysis of blood pressure (BP) reductions with olmesartan medoxomil (OM) compared with active control (AC) in patients (pts) with hypertension (HTN) (2015) (0)
PP.07.16: META-ANALYSIS OF BLOOD PRESSURE REDUCTIONS WITH OLMESARTAN MEDOXOMIL IN CLINICAL COMPARISONS WITH ACTIVE CONTROLS IN PATIENTS WITH HYPERTENSION (2015) (0)
The effect of visit-to-visit variability in blood pressure on stroke and coronary events in 5213 patients with diabetes: pooled analyses of TNT, IDEAL, and CARDS trials (2012) (0)
High Frequency of Unrecognized Diabetes in Cardiovascular Patients: Should All Have an Oral Glucose Tolerance Test? (2008) (0)
Second hand smoke and hypercholesterolemia increase arterial matrix metallproteinase activity (1998) (0)
Avoid the rush to judgment in acute coronary syndromes. (2005) (0)
Relationship Between Plasma Glucose and Mortality in Non-Diabetic Patients With Acute Coronary Syndrome and Systolic Heart Failure: Insights From the EPHESUS Trial (2010) (0)
Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with preserved ejection fraction and persistent hypertension. (2022) (0)
Patients by Lipid and Nonlipid Biomarkers Prediction of Cardiovascular Events in Statin-Treated Stable Coronary (2012) (0)
PP.21.16: META-ANALYSIS OF OLMESARTAN-BASED SINGLE PILL COMBINATION VERSUS MONOTHERAPY FOR REDUCING BLOOD PRESSURE (2015) (0)
Silent myocardial ischemia : the cardiologist's perspective on mechanisms, prevalence, and treatment (1991) (0)
Imaging Modality for Left Ventricular Ejection Fraction Estimation and Effect of Implantable Cardioverter Defibrillator on Mortality in Patients with Heart Failure. (2023) (0)
PRIOR HEART FAILURE (HF) HOSPITALIZATION AND 30-DAY AND 1-YEAR OUTCOMES IN PATIENTS WITH HF AND PRESERVED EJECTION FRACTION (HFPEF) (2018) (0)
AMONG OLDER HEART FAILURE (HF) PATIENTS WITH IN-HOSPITAL ACUTE KIDNEY INJURY (AKI), AN IMPROVEMENT IN KIDNEY FUNCTION IS ASSOCIATED WITH A HIGHER RISK OF POST-DISCHARGE MORTALITY BUT NOT READMISSION (2017) (0)
Therapeutic Implications (2005) (0)
All ACE Inhibitors Are Not Alike-Reply (1991) (0)
Abstract 11525: Physical Activity and Incident Heart Failure in Community Dwelling Older Adults with and without Metabolic Syndrome (2011) (0)
Abstract 1707: Admission Glucose and Cardiovascular Outcomes in Patients With Non-ST Elevation ACS: Observations From the MERLIN-TIMI 36 Trial (2009) (0)
Encainide and flecainide increased mortality in patients with asymptomatic or mildly symptomatic ventricular arrhythmias (1991) (0)
Prevention of cardiovascular disease : a continuum (2011) (0)
Is the Measurement of B-Type Natriuretic Peptide in the Emergency Room Useful in Established Congestive Heart Failure Exacerbation? (2009) (0)
Discussion 1 : Pharmacology , Pharmacodynamics and Pharmacokinetics of Sotalol (1990) (0)
Abstract 12580: Intensive Lipid Lowering with Atorvastatin in Patients with Treatment Resistant Hypertension: An Analysis from the Treating to New Targets (TNT) Trial (2012) (0)
Intensive lipid-lowering is no more effective than diet and low-dose lovastatin for reducing ischaemia in people with heart disease. Commentary. (2005) (0)
Silent ischaemia: to treat or not to treat? (1996) (0)
CHRONIC ALPHA BLOCKER USE AND OUTCOMES IN OLDER MALE MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE (2017) (0)
Interventions for Cardiovascular Prevention (2011) (0)
Heart failure in the elderly: is beta-blockade the standard of care? (2002) (0)
the BEST trial The effect of diabetes on outcomes of patients with advanced heart failure in (2011) (0)
Abstract 18743: Lack of Evidence of Higher 30-day All-cause Readmission Among Older African American (vs. White) Medicare Beneficiaries Hospitalized for Heart Failure (2015) (0)
Physical Activity, and Metabolism American Heart Association Diabetes Committee of the Council on Nutrition, Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement From the (2008) (0)
Abstract 19151: Clinical Predictors of Response to Beta-Blocker Therapy in Patients with Heart Failure and Reduced Ejection Fraction due to Non-Ischemic Cardiomyopathy (2014) (0)
Comparative efficacy of enoximone vs captopril in moderate heart failure (1989) (0)
Statement of the American Diabetes Association and a Scientific Statement of the Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Intensive Glycemic Control and the Prevention of Cardiovascular Events: (2009) (0)
Moderated ePoster Session 2 (2014) (0)
on Sinus NodeandAtriuminPatients withandwithout Sinoatrial Dysfunction (1977) (0)
Abstract 18927: Systolic Blood Pressure (SBP) <130 mmHg and Outcomes in Patients With Heart Failure and Preserved Ejection (HFpEF) and Hypertension (HTN) (2017) (0)
O212 Predictive Value of Lipoprotein Parameters on the Risk of Chronic Kidney Disease in Patients with Coronary Heart Disease (2014) (0)
Abstract 12927: Concurrent Pneumonia has no Association With 30-Day All-Cause or Heart Failure Readmissions but is Associated With Higher 30-Day Pneumonia Readmission and MayBe Associated With Higher 30-Day All-Cause Mortality in Older Medicare Beneficiaries Hospitalized for Heart Failure (2015) (0)
Does the Effect of Beta-Blockers on Outcomes in Patients with Advanced Chronic Systolic Heart Failure Vary by Baseline Systolic Blood Pressure? Insights from the BEST Trial (2010) (0)
Chapter-06 Management of Patients with Chronic Coronary Artery Disease and Stable Angina (2014) (0)
Review: Rosiglitazone increases risk for cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes (2011) (0)
Abstract 18879: Low Income is Associated With Higher Risk of Cardiovascular Events and Mortality in Community Dwelling, Medicare Eligible, College Educated Older Adults With Background Professional Occupation (2013) (0)
Pulmonary Effect of Amiodarone in Patients With Heart Failure fn1fn1This study was supported by the Department of Veterans Affairs Cooperative Studies Program of the Medical Research Service (Washington, D.C.), Sanofi Winthrop Recherche (Paris, France) and Wyeth-Ayerst Laboratories (Philadelphia, Pe (1997) (0)
Comprar Drug And Device Selection In Heart Failure | Prakash C. Deedwania | 9789350907238 | Jaypee (2014) (0)
The Role of Aldosterone Blockade in Post-MI Heart Failure (2006) (0)
Irregular heart rate: A six-article symposium (1988) (0)
Contents (1966) (0)
New Risk Factors of Cardiovascular Disease (2015) (0)
Living alone after myocardial infarction was an independent risk factor for recurrent events (1992) (0)
Heart Failure Hospitalization (HFH) Despite Digoxin Therapy Versus No HFH Despite Placebo in the Digitalis Investigation Group (DIG) Trial: Insights Into Risk Factors for HFH in hf and Reduced Ejection Fraction (HFrEF) (2017) (0)
SELF-REPORTED LOWER EXTREMITY EDEMA IN THE ABSENCE OF HEART FAILURE IS AN INDEPENDENT RISK FACTOR FOR INCIDENT HEART FAILURE AMONG COMMUNITY-DWELLING OLDER ADULTS (2015) (0)
Systematic review and pooled analysis of randomised controlled clinical trials of cilnidipine under ambulatory blood pressure monitoring setting (2016) (0)
The Impact of Moderate Elevations of Blood Pressure and Low-Density Lipoprotein Chlosterol on Coronary Heart Disease Risk (2013) (0)
Abstract 18094: Multimorbidity and 30-Day All-Cause Readmission Among Hospitalized Medicare Beneficiaries With Heart Failure (2013) (0)
Is there a need for multiple cardiac enzymatic values for the diagnosis of myocardial infarction (1998) (0)
Abstract 3729: High-Dose Atorvastatin Attenuates Cardiovascular Risk Prediction of the Metabolic Syndrome Components (2007) (0)
Time series pattern recognition using chaotic analysis (2000) (0)
Abstract 20721: Death Despite Enalapril Therapy vs. Survival Despite Placebo in the Studies of Left Ventricular Dysfunction (SOLVD) Trial: Insights into the Role of Traditional Risk Factors for Mortality in Heart Failure and Reduced Ejection Fraction (HFrEF) (2016) (0)
Abstract 15862: Epidemiology and Outcomes of Resistant Hypertension in 5788 Community-Dwelling Older Adults (2011) (0)
482 C-REACTIVE PROTEIN (CRP) AND LIPID LEVELS TO PREDICT THE RISK OF CORONARY HEART DISEASE IN STATIN-TREATED STABLE CORONARY PATIENTS (2011) (0)
Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart (2011) (0)
Abstract 17121: Initiation of Anti-Hypertensive Therapy and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and a History of Hypertension (HTN) (2020) (0)
784 INCREASED CARDIOVASCULAR EVENT RATE IN STABLE CORONARY PATIENTS WITH METABOLIC SYNDROME COMPLICATED BY CHRONIC KIDNEY DISEASE IS REDUCED BY ATORVASTATIN (2011) (0)
1013-108 Is Persantine Thallium Scintigraphy Cost Effective and Reliable in the Preoperative Evaluation of Patients Referred for Peripheral Vascular Surgery? (1995) (0)
Abstract 14895: Predictors of Six-Month Mortality for Older Medicare Beneficiaries Hospitalized for Heart Failure: Plans for the Development and Validation of University of Alabama at Birmingham Heart Failure Model to Optimize Discharge Hospice Referral (2014) (0)
Chapter-031 State-of-the-art Review on Metabolic Syndrome, Diabetes, and Cardiovascular Disease (2015) (0)
Angiotensin Receptor Blockers: Cardiovascular Protection in the Metabolic Syndrome (2006) (0)
INITIATION OF ANTI-HYPERTENSIVE DRUGS AND OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) (2020) (0)
Prevalence of silent ischemia during holter monitoring in diabetic versus non-diabetic patients with stable angina (1990) (0)
Aggressive lipid lowering with atorvastatin reduces increased risk of cardiovascular events in patients with metabolic syndrome and coronary heart disease (2006) (0)
Abstract 17143: Shorter Length of Stay is Associated With Significantly Lower 30-day All-cause Readmission and 30-day All-cause Mortality in Older Medicare Beneficiaries Hospitalized for Heart Failure (2015) (0)
MORTALITY IN HEART FAILURE WITH INDETERMINATE KIDNEY DISEASE (2023) (0)
Chapter-06 Drugs for Diabetes and Cardiodysmetabolic Syndrome (2013) (0)
Learning the True Lessons of PEACE (2005) (0)
ORTHOPNEA OR PAROXYSMAL NOCTURNAL DYSPNEA IN OLDER ADULTS WITHOUT PREVALENT HEART FAILURE IS A PREDICTOR, BUT NOT AN INDEPENDENT RISK FACTOR FOR INCIDENT HEART FAILURE: INSIGHTS FROM THE CARDIOVASCULAR HEALTH STUDY (2017) (0)
Diagnostic and therapeutic implications: exploration through case discussions. (1992) (0)
Abstract 17511: Discharge Initiation of Beta Blocker Therapy is Associated With Significantly Lower 30 Day Mortality Without Associated Increase in 30 Day All Cause Readmission in Hospitalized Older Patients With Heart Failure and Reduced Ejection Fraction (2013) (0)
Should an Aldosterone Blocker Be Added to an ACE Inhibitor and Beta Blocker in Heart Failure (2020) (0)
56 Withdrawn Effects of intensive lipid lowering with atorvastatin on congestive heart failure: subgroup analysis of the Treating to New Targets (TNT) study (2006) (0)
Abstract 1182: High Frequency of Unrecognized Diabetes in Cardiovascular Patients: Should All Have an Oral Glucose Tolerance Test? (2008) (0)
HIGH-DOSE ATORVASTATIN ATTENUATES CARDIOVASCULAR RISK PREDICTION OF THE METABOLIC SYNDROME COMPONENTS: THE TREATING TO NEW TARGETS STUDY (2008) (0)
Abstract 17428: Discharge Prescriptions for Spironolactone and 30-day All-cause Readmission in Hospitalized Medicare Beneficiaries With Heart Failure, LVEF Less Than 45% and eGFR Less Than 45 (2013) (0)
Epidemic of Cardiovascular Disease? Metabolic Syndrome and Vascular Disease : Is Nature or Nurture Leading the New (2013) (0)
ASSOCIATIONS OF SYSTOLIC BLOOD PRESSURE (SBP) <120 (VERSUS 120-139) MMHG WITH OUTCOMES IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION (HFPEF) WITHOUT HYPERTENSION (HTN) (2018) (0)
Valsartan improves early morning adn 24-hour heart rate variability (2003) (0)
Abstract 15283: Metabolic Syndrome and Cardiovascular Events in Statin-Treated Stable Coronary Patients: Prospective Results From the TNT Study (2010) (0)
Adverse Outcomes With Use of Hydralazine and Nitrate Combination Therapy in Hospitalized Older Non-black Patients With Heart Failure and Reduced Ejection Fraction (HFREF) (2017) (0)
Abstract 985: Renin-Angiotensin System (RAS) Blockade Ameliorates Diuretic Induced Hyperglycemia in Obese Hypertensive Normoglycemic or Prediabetic Individuals (2009) (0)
Atrial Fibri l lation in Heart Failure (0)
Abstract 17157: Clinical Impact of Digoxin Discontinuation at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction (2018) (0)
Efficacy of Nicardipine for Long-Term Therapy of Chronic Stable Angina (1998) (0)
PO23-733 INTENSIVE ATORVASTATIN THERAPY IS ASSOCIATED WITH SIGNIFICANT CARDIOVASCULAR BENEFITS IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE: THE TNT STUDY (2007) (0)
SECONDHAND SMOKE IS LINKED TO HIGHER RISK OF NON-CARDIOVASCULAR MORTALITY BUT NOT OF CARDIOVASCULAR MORTALITY IN COMMUNITY-DWELLING OLDER ADULTS: FINDINGS FROM CARDIOVASCULAR HEALTH STUDY (CHS) (2018) (0)
IMPROVEMENT IN EGFR WITH ATORVASTATIN MAY CONTRIBUTE TO REDUCTIONS IN HOSPITALIZATIONS FOR CONGESTIVE HEART FAILURE: TREATING TO NEW TARGETS (TNT) STUDY (2011) (0)
HIGH-DOSE BETA-BLOCKERS (BB) AND OUTCOMES IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION (HFPEF) AND HEART RATE ≥70 BEATS PER MINUTE (BPM) (2018) (0)
A career spanning from heart failure to preventive cardiology and lipidology (2014) (0)
P Heart Failure hat Resting Heart Rate Should ne Aim For When Treating Patients ith Heart Failure With a Beta-Blocker ? xperiences From the Metoprolol Controlled Release / Extended Release andomized Intervention Trial in Chronic Heart Failure ( MERIT-HF ) (2016) (0)
Does Response of RAS Blockade on Serum K+ Levels Influence Its Glycemic‐Mitigating Response When Combined With Hydrochlorothiazide? (2012) (0)
Vascular Protection After the PEACE Trial (2005) (0)
Clinical efficacy and cost–effectiveness of rosuvastatin (2007) (0)
CLINICAL DETERMINANTS OF INCIDENT AORTIC STENOSIS IN STATIN–TREATED STABLE CORONARY PATIENTS (2013) (0)
EARLY (1-10 DAYS) READMISSION IS ASSOCIATED WITH A SIGNIFICANTLY LOWER 2-12 MONTHS POST-DISCHARGE ALL-CAUSE MORTALITY AMONG OLDER MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE WITH 30-DAY ALL-CAUSE READMISSIONS (2016) (0)
Abstract 16098: Risk Factors for Frequent Premature Atrial Complexes in a Ten Year Holter Cohort (2014) (0)
Vitamin E restores impaired acetyicholine-mediated vasodilatation secondary to environmental tobacco smoke (1996) (0)
The Association of Metabolic Syndrome and Insulin Resistance with Incident Heart Failure is Independent of Each Other and Other Risk Factors including C-Reactive Protein (2010) (0)
Cholesterol lowering in patients with CHD and metabolic syndrome – Authors' reply (2007) (0)
ADMISSION-TO-DISCHARGE WEIGHT CHANGE AND 30-DAY POST-DISCHARGE OUTCOMES IN OLDER PATIENTS WITH HEART FAILURE WITH PRESERVED AND REDUCED EJECTION FRACTION (HFPEF AND HFREF) (2019) (0)
Almost one third of the patients had more of the amino acid homocyst(e)ine in their blood serum than did the healthy volunteers with no history of CV disease (1990) (0)
Admission Electrocardiogram Diagnosed Atrial Fibrillation is Independently Associated with 30-Day All-Cause Readmission in Older Medicare Beneficiaries Hospitalized for Heart Failure (2016) (0)
Abstract 14422: Frequent Premature Atrial Complexes and their Association With Risk of Atrial Fibrillation (2013) (0)
Comprar Prevention of Cardiovascular Disease: A Continuum, An Issue of Cardiology Clinics | Prakash C. Deedwania | 9781455704262 | Saunders (2011) (0)
Single-photon emission tomography was accurate for investigating coronary artery disease (1991) (0)
CARDIOVASCULAR EVENT RATES IN STABLE CORONARY PATIENTS WITH CHRONIC KIDNEY DISEASE, INCREASED BY THE PRESENCE OF OBESITY, ARE REDUCED BY INTENSIVE LIPID LOWERING WITH ATORVASTATIN (2010) (0)
Abstract 15658: Determinants of Residual Risk in 9,251 Secondary Prevention Patients Treated with High- versus Low-dose Statin Therapy: The Treating to New Targets (TNT) Study (2011) (0)
Perioperative beta blocker therapy is not ready to vanish yet (2017) (0)
Abstract 20566: Lower Discharge Systolic Blood Pressure (SBP) and Poor Outcomes among Hospitalized Patients With Heart Failure and Preserved Ejection Fraction (HFpEF) and Stable Admission-to-Discharge SBP (2016) (0)
Antioxidant dietary suppelementation with vitamin E decreased atherosclerosis and cellular proliferation in lipid-fed rabbits exposed to passive smoking (1996) (0)
Abstract 20752: Clinical Effectiveness of Digoxin in Hospitalized Older Patients With Heart Failure and Preserved Ejection Fraction: A Propensity-Matched Study of Medicare-Linked OPTIMIZE-HF (2016) (0)
Current Smoking and a “Non-Paradoxical” Association with Mortality among Community-Dwelling Older Heart Failure Patients: Findings From the Cardiovascular Health Study (2016) (0)
Is anterior wall involvement in non-Q wave myocardial infarction associated with left ventricular dysfunction? (1997) (0)
CLINICAL EFFECTIVENESS OF SPIRONOLACTONE IN HOSPITALIZED OLDER ELIGIBLE (EF LESS THAN OR EQUAL TO 35% AND EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M2) PATIENTS WITH HEART FAILURE (2017) (0)
PROLONGED CARDIOVASCULAR RISK AFTER ≥15 YEARS SMOKING CESSATION IN OLDER FORMER SMOKERS (2022) (0)
Abstract 15946: Heart Failure With Preserved Ejection Fraction (HFpEF) and Atrial Fibrillation (AF) is Prognostically Equivalent to HF With Reduced Ejection Fraction (HFrEF) With or Without AF Among Community-Dwelling Older Adults (2014) (0)
IS ISOLATED DIASTOLIC HYPOTENSION A NEW RISK FACTOR FOR INCIDENT HEART FAILURE IN COMMUNITY-DWELLING OLDER ADULTS? (2010) (0)
Oral insulin: an update. (2020) (0)
AHA/ADA Scientific Statement (2015) (0)
Chapter 43 – Hypertension in South Asians (2013) (0)
Chronic intraventricular conduction defects. (1980) (0)
Electrophysiologic studies in cardiac arrhythmia. When and why they are useful. (1988) (0)
The Role of Electronic Medical Records (EMR) Innovations in Identifying Chronic Heart Failure (CHF) Self Care Knowledge Gaps: A Nursing Assessment Tool To Customize Patient Education at Point of Care (2010) (0)
DISCHARGE HOME HEALTH REFERRAL IS ASSOCIATED WITH HIGHER POST-DISCHARGE 30-DAY ALL-CAUSE READMISSION AND ALL-CAUSE MORTALITY AMONG OLDER MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE (2016) (0)
INITIATION OF LOOP DIURETICS HAS NO ASSOCIATION WITH 30-DAY ALL-CAUSE OR HEART FAILURE READMISSIONS OR ALL-CAUSE MORTALITY IN OLDER MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE (2016) (0)
Longterm efficacy of Nicardipine alone and in combination with beta-blockers in stable angina (1991) (0)
Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET? (2008) (0)
INTENSIVE LIPID LOWERING WITH ATORVASTATIN IS ASSOCIATED WITH SIGNIFICANT CARDIOVASCULAR BENEFITS IN CORONARY PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE (2008) (0)
THE EFFECT OF BETA-BLOCKERS ON MORTALITY IN SYSTOLIC HEART FAILURE VARIES BY BASELINE RIGHT VENTRICULAR EJECTION FRACTION: A POST HOC ANALYSIS OF THE BEST TRIAL (2011) (0)
Abstract 410: Link Between Hypertension and Insulin Resistance in South Asians: Implications for Prevention of Cardiovascular Complications (2016) (0)
LOW INCOME IS LINKED TO A HIGHER RISK OF MORTALITY AND INCIDENT CARDIOVASCULAR (CV) EVENTS IN OLDER ADULTS: A 23-YEAR FOLLOW-UP OF CARDIOVASCULAR HEALTH STUDY (CHS) (2020) (0)
A New Exercise Criterion for Identification of Multi-vessel Coronary Artery Disease In Patients Receiving Antianginal Therapy: Change in Recovery Double Product (0435) (1989) (0)
Does prolonged duration of silent ischemia during Holter monitoring identify patients at higher risk of cardiac death (1991) (0)
GPIIB/IIIA INHIBITORS USE IMPROVES OUTCOMES AFTER ASPIRATION THROMBECTOMY IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION: A METAREGRESSION ANALYSIS (2015) (0)
Identification of Patients with Coronary Artery Disease Using a Stress‐Free Signal Variance Cardiograph Through Analysis of Temporal Heterogeneity (1996) (0)
768 CARDIOVASCULAR EVENT RATE IN STABLE CORONARY PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) INCREASED BY BEING OBESE IS REDUCED BY ATORVASTATIN (2011) (0)
INCREASED CARDIOVASCULAR EVENT RATE OBSERVED IN STABLE CORONARY PATIENTS WITH METABOLIC SYNDROME COMPLICATED BY CHRONIC KIDNEY DISEASE IS REDUCED BY INTENSIVE LIPID LOWERING WITH ATORVASTATIN (2010) (0)
Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease. (2023) (0)
PW219 Prevalence Of Metabolic Syndrome And Association With Lifestyle Factors In India: A Nationwide Cross Sectional Study In Urban Subjects (2014) (0)
Exercise induced angina is predictive of high-risk thallium defects in patients with non-Q wave myocardial infarction (1996) (0)
Abstract 17118: Isolated Diastolic Hypotension Without Systolic Hypotension or Hypertension is an Independent Risk Factor for Incident Heart Failure Among Community-Dwelling Older Adults (2011) (0)
Relationship Between Admission Glucose Level and Outcomes in ACS Patients With and Without Preexisting Diabetes Mellitus (2008) (0)
Chapter-03 Guideline-Based Standard Therapy for Heart Failure: The Role of RAAS Blockers and Beta Blockers (2014) (0)
Abstract 20782: Discharge Hospice Referral is Associated With Lower 30-Day All-Cause Readmission in Hospitalized Patients With Heart Failure: A Propensity-Matched Study of the Medicare-Linked OPTIMIZE-HF (2016) (0)
Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure Subgroup Analysis of the Treating to New Targets (TNT) Study Heart Failure (2007) (0)
Abstract 19094: Use of ACE Inhibitors or Angiotensin Receptor Blockers is Associated With a Significantly Lower Risk of 30-day All-cause and Heart Failure Readmissions and All-cause Mortality in Older Medicare Beneficiaries Hospitalized for Heart Failure Developing Acute Kidney Injury (2015) (0)
Clinical Implications of Recent Therapeutic Trials in Hypertension: Insights from SPRINT and HOPE-3 Trials (2016) (0)
1015-70 Silent Ischemia During Daily Life is an Independent Predictor of Poor Clinical Outcome and Increased Risk of Cardiac Death (1995) (0)
Abstract 10651: Intensive Lipid Lowering with Atorvastatin is Effective in Significantly Reducing Coronary Risk in Both Obese and Morbidly Obese Patients (2011) (0)
Abstract 18350: Impact of Amount vs Duration of Smoking on Incident Heart Failure and Mortality Among Community-dwelling Older Adults: Need to Reassess the Role of Pack-years as a Tool to Estimate Smoking (2015) (0)
A Hybrid System for Chest pain Analysis (1993) (0)
Cardiovascular outcomes in community-dwelling older adults with chronic obstructive pulmonary disease (2013) (0)
OUTCOME DIFFERENCES BETWEEN PREVALENT USERS VS. NEW USERS OF THE SAME DRUG: WHEN DRUG EFFECT OR SELECTION BIAS CANNOT EXPLAIN POOR OUTCOMES AMONG PREVALENT USERS (2022) (0)
Prognostic significance of standard ECG in nonischemic dilated cardiomyopathy (2003) (0)
Reply: To PMID 24846806. (2015) (0)
Abstract 572: Hyperglycemia and Poor Outcomes in Patients without Diabetes Mellitus in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS): A Propensity Matched Analysis (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Prakash C. Deedwania?

Prakash C. Deedwania is affiliated with the following schools:

Prakash C. Deedwania's Academic­Influence.com Rankings

Prakash C. Deedwania's Degrees

Why Is Prakash C. Deedwania Influential?

Prakash C. Deedwania's Published Works

Published Works

What Schools Are Affiliated With Prakash C. Deedwania?

Prakash C. Deedwania's AcademicInfluence.com Rankings